Brief: KDventures: AnaCardio's AC01 Study Published
25/06/2026 09:11
BRIEF-KDventures: AnaCardio's AC01 Study Published June 25 (Reuters) - Kdventures AB KDV.ST:
PORTFOLIO COMPANY ANACARDIO'S CLINICAL STUDY OF DRUG CANDIDATE AC01 PUBLISHED IN THE LANCET
STUDY SHOWS FAVORABLE SAFETY PROFILE AND SUSTAINED EFFECTS ON CARDIAC FUNCTION IN HFREF PATIENTS
PHASE 2B STUDY OF AC01 IN HFREF PATIENTS EXPECTED TO BEGIN LATER IN 2026
Source text: ID:nMFNyvxZM
Further company coverage: KDV.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Kdventures AB
See all newsRefile: BRIEF-Umecrine Cognition Gets Notice Of Allowance In US
Brief: KDventures' Modus Therapeutics Pauses Enrollment In Phase 2A Study
Brief: KDventures' AnaCardio Raises €62.5 Million
Brief: Kdventures' Umecrine Cognition Gets Two USPTO Notices Of Allowance For Patent Applications
Brief: Kdventures' Modus Therapeutics Carries Out Directed Issue